Eating disorders are disorders that can cause serious and fatal illness in the body. There are several types of eating disorders such as anorexia nervosa, bulimia nervosa, emotional overeating, binge eating disorder, and others. People with anorexia nervosa consider themselves as overweight even when they are dangerously underweight. People with bulimia nervosa generally have frequent episodes of uncontrollable eating. People with binge eating disorder generally have no control over eating and they are often obese. The risk factors associated with eating disorders can be social, genetic, psychological, and behavioural. Takeda Pharmaceutical Company Limited is in the process of developing vortioxetine as a serotonin 1A receptor agonist for the treatment of binge eating disorder. Sunovion Pharmaceuticals, Inc. is in the process of developing dasotraline as an adrenergic uptake inhibitor for the treatment of binge eating disorder. Some of the companies and universities having the pipeline of eating disorder include University of Cincinnati, Sunovion Pharmaceuticals, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.